Novogenia AG
6.75
EUR
+0.10
(+1.50%)
ISIN
DE000A3C35W0
Return %
Stock
S&P 500
1Y
-4.26
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.Company Description
- CEO
- Daniel Wallerstorfer
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Munich Germany
- IPO Date
- Nov 2, 2021
- Website
- novogenia.com
- Similar Companies
- Business
- Novogenia AG is a biotechnology and personalized healthcare company that develops, manufactures, and commercializes genetic diagnostics, preventive medical solutions, and individualized health and wellness products. The company operates an integrated value chain spanning DNA analysis, laboratory diagnostics, bioinformatics data interpretation, and automated custom manufacturing. Its primary product and service offerings comprise genetic testing panels, including preventive screening, pharmacogenetics, nutrigenetics, lifestyle profiling, and specialized clinical genetics; diagnostic laboratory services, including high-throughput polymerase chain reaction testing, virological diagnostics, and biochemical blood analysis; specialized oncology diagnostics, featuring the Multi-Cancer Check blood screening test for early detection across multiple cancer types; advanced metabolic diagnostics, including the comprehensive MGT Plus methylation test; customized dietary supplements, formulated and manufactured on an individualized basis utilizing personal genetic and biomarker profiles; and personalized skincare formulations and therapeutic cosmetics tailored to individual dermatological requirements. The company interprets complex genetic data using proprietary algorithmic platforms, including its Deep Genome AI system. Novogenia AG serves medical practices and physicians through its NovoMedic division; pharmacies via its GGENius subsidiary; direct-to-consumer channels through its 305 Care brand; and institutional clients, pharmaceutical partners, and specialized clinics across Europe and North America. Founded in 2009, the company is headquartered in Munich, Germany, and maintains its principal laboratory and production facilities in Eugendorf, Austria. Key corporate subsidiaries include Novogenia GmbH, NovoMedic GmbH, GGENius GmbH, 305Care GmbH, HLN Genetik GmbH, Mendelio Srl, Darwin Pharma Holding GmbH, Medicopharm AG, INOPHA GmbH, and ChiruTec GmbH. In recent developments, the company executed a corporate name change from Darwin AG to Novogenia AG in July 2026 to consolidate its global brand identity and support international expansion in personalized longevity solutions. In August 2026, Novogenia AG entered the United States market through a strategic partnership with 10X Health to distribute its 27-gene MGT Plus methylation test. In July 2026, the company broke ground on a new 9,300-square-meter campus in Hallwang, Austria, designed for robotic manufacturing, laboratory diagnostics, and research and development. Recent commercial launches include the rollout of the Multi-Cancer Check early detection assay and the commercial deployment of the 305 Care consumer cosmetics line. On the corporate development front, the group fully consolidated pharmaceutical entity Medicopharm AG following earlier acquisitions of medical distribution businesses INOPHA GmbH and ChiruTec GmbH, and completed a one-to-three share split to support equity trading liquidity across German exchanges.